🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

US STOCKS-Wall Street gains on Boeing news, Trump's reopening plan

Published 04/18/2020, 03:25 AM
Updated 04/18/2020, 03:30 AM
© Reuters.
US500
-
DJI
-
GILD
-
AAPL
-
IXIC
-
SPSY
-

(For a live blog on the U.S. stock market, click LIVE/ or
type LIVE/ in a news window)
* Boeing to resume airplane production in Washington state
* Gilead surges on report of positive data from COVID-19
trial
* Indexes rise: Dow 1.9%, S&P 500 1.7%, Nasdaq 0.5%

(Updates to late afternoon)
By Caroline Valetkevitch
April 17 (Reuters) - U.S. stocks rose on Friday, helped by a
surge in Boeing shares, President Donald Trump's plan to reopen
the economy and hopes of a potential drug by Gilead to treat
COVID-19.
Shares of the U.S. planemaker BA.N soared on plans to
restart commercial jet production in Washington state after
halting operations last month due to the coronavirus pandemic.
The S&P 500 was up sharply from its March trough and set to
gain for the week following a raft of global stimulus and on
hopes that statewide lockdowns would be eased as the outbreak
showed signs of ebbing.
However, the index remains well off its all-time high and
strategists have warned of a deep economic slump as a halt in
business activity puts millions of Americans out of work.
Some U.S. states on Friday were expected to announce
timetables for lifting restrictions, a day after Trump outlined
guidelines for a phased reopening of the devastated U.S.
economy. The plans "provide some hope and optimism for folks and the
market and the whole economy. It's a start," said Gary Bradshaw,
portfolio manager at Hodges Capital Management in Dallas.
The news on Boeing, which Bradshaw says his firm owns, has
helped lift optimism as well.
Gilead Sciences Inc GILD.O surged 8.1% following a report
that patients with severe symptoms of COVID-19, the respiratory
disease caused by the coronavirus, had responded positively to
its experimental drug, remdesivir. With no treatments or vaccines currently approved for the
coronavirus, the news lifted global equity markets, but Gilead
said the totality of the data from the trial needed to be
analyzed and it expected to report results from a study in
severe COVID-19 patients at the end of April. The Dow Jones Industrial Average .DJI rose 445.98 points,
or 1.89%, to 23,983.66, the S&P 500 .SPX gained 47.29 points,
or 1.69%, to 2,846.84 and the Nasdaq Composite .IXIC added
40.45 points, or 0.47%, to 8,572.81.
Bank stocks .SPXBK recovered after four straight days of
losses triggered by lenders reporting several billion dollars in
reserves to cover potential loan defaults. Financial stocks
.SPSY were the top boost to the S&P 500.
Apple Inc AAPL.O fell as Goldman Sachs downgraded the
stock on expectations of a 36% drop in iPhone shipments during
the third quarter due to coronavirus-related lockdowns.
Advancing issues outnumbered declining ones on the NYSE by a
4.96-to-1 ratio; on Nasdaq, a 3.58-to-1 ratio favored advancers.
The S&P 500 posted eight new 52-week highs and no new lows;
the Nasdaq Composite recorded 28 new highs and nine new lows.


Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.